Aminoacyl-tRNA synthetases are a class of enzymes that charge tRNAs with their cognate amino acids. The protein encoded by this gene is a cytoplasmic enzyme which belongs to the class II family of aminoacyl-tRNA synthetases. The enzyme is responsible for the synthesis of histidyl-transfer RNA, which is essential for the incorporation of histidine into proteins. The gene is located in a head-to-head orientation with HARSL on chromosome five, where the homologous genes share a bidirectional promoter. The gene product is a frequent target of autoantibodies in the human autoimmune disease polymyositis/dermatomyositis.

Histidyl-tRNA synthetase human recombinant produced in E. coli is a single, non-glycosylated, polypeptide chain having a molecular mass of 55 kDa. The histidyl-tRNA synthetase is purified by a proprietary chromatographic technique. Purity is greater than 90.0% as determined by both RP-HPLC and SDS-PAGE. The protein solution contains 150 mM NaCl and 10 mM sodium phosphate containing 0.1% NaN3 (pH 7.2). Protein quantitation was carried out by using 0.25 – 2.0 mg/ml Bradford assay vs. BSA.

Reported to be effective for immunoblotting (western blot, strongly reactive with human anti-histidyl-tRNA synthetase antisera).

To view protocol(s) for this and other products please visit: www.ATSbio.com/support/protocols

Advanced Targeting Solutions（ATS）是一家位于圣地亚哥的生物技术公司，致力于为科学研究和药物开发提供高质量的靶向试剂。ATS被称为“萨波林人”，最初致力于为神经科学研究界提供研究工具。多年来，这些工具已用于科学研究和药物开发的所有领域。公司目前的产品线包括针对性毒素，抗体和定制服务，旨在帮助科学家研究系统功能，细胞功能，疾病和病症。ATS率先将靶向结合物用于“分子手术”技术。这些产品包括针对胆碱能性前脑神经元，去甲肾上腺素能和肾上腺素能神经元，巨噬细胞和小胶质细胞的特定损伤剂，以及能侵袭所有神经元上表达的抗原决定簇的泛神经元剂。此外，ATS还出售“次级结合物”，使用户可以将自己的靶向剂转化为特定的细胞毒性工具，并筛选抗体进行内在化。ATS已商业化，并提供了由Douglas Lappi博士开发和完善的Saporin技术平台的访问权限。拉皮博士与医学博士Ronald Wiley合作。在他们的学术实验室中，以验证使用主要的皂素结合物192-IgG-SAP来建立阿尔茨海默氏病模型。丹妮丝·希金斯（Denise Higgins）将她的业务专长和国际销售/营销经验带到了团队中，并将继续致力于将这一创新技术带给全球科学家。